<h1 id="nsaids-and-upper-gi-bleed">NSAIDs and Upper GI Bleed</h1>
<ul>
<li>Stomach and platelets have much more COX-1 receptors than COX-2 receptors.</li>
<li>Below are statistics from systematic review on NSAIDs and upper GI complications(bleeding, perforation)</li>
</ul>
<p><strong>Ketorolac pearls</strong></p>
<ul>
<li>Has the highest upper GI complication RR (14.54)</li>
<li>Before giving, first check that patients don&#39;t have a history of a GI bleed or peptic ulcer</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAID medication</strong></td>
<td><strong>Relative risk of complication</strong></td>
<td><strong>[95 % CI]</strong></td>
</tr>
<tr>
<td>COX-1 Inhibitors (all)</td>
<td>4.5</td>
<td>[3.82-5.31]</td>
</tr>
<tr>
<td>- <span class="drug">Ibuprofen</span></td>
<td>2.69</td>
<td>[2.17-3.33]</td>
</tr>
<tr>
<td>- <span class="drug">Diclofenac</span>*</td>
<td>3.98</td>
<td>[3.36-4.72]</td>
</tr>
<tr>
<td>- <span class="drug">Meloxicam</span>*</td>
<td>4.15</td>
<td>[2.59-6.64]</td>
</tr>
<tr>
<td>- <span class="drug">Indomethacin</span>*</td>
<td>5.40</td>
<td>[4.16-7.00]</td>
</tr>
<tr>
<td>- <span class="drug">Ketoprofen</span>*</td>
<td>5.57</td>
<td>[3.94-7.87]</td>
</tr>
<tr>
<td>- <span class="drug">Naproxen</span>*</td>
<td>5.63</td>
<td>[3.83-8.28]</td>
</tr>
<tr>
<td>- <span class="drug">Piroxicam</span></td>
<td>9.94</td>
<td>[5.99-16.50]</td>
</tr>
<tr>
<td>- <span class="drug">Ketorolac</span></td>
<td>14.54</td>
<td>[5.87-36.04]</td>
</tr>
<tr>
<td>COX-2 Inhibitors (all)</td>
<td>1.88</td>
<td>[0.96-3.71]</td>
</tr>
<tr>
<td>- <span class="drug">Celecoxib</span></td>
<td>1.42</td>
<td>[0.85-2.37]</td>
</tr>
<tr>
<td>- <span class="drug">Aceclofenac</span></td>
<td>1.44</td>
<td>[0.65-3.2]</td>
</tr>
<tr>
<td>- <span class="drug">Rofecoxib</span></td>
<td>2.12</td>
<td>[1.59-2.84]</td>
</tr>
</tbody>
</table>
<p><em>\</em> = Estimated relative risk*</p>
<h2 id="risk-factors-for-upper-gi-complication">Risk Factors for Upper GI Complication</h2>
<ol>
<li><span class="aglmd-moreinfo ui-moreinfo" data-iid="53aa2488d35d3ae92e001f47">Longer drug half-life</span></li>
<li>Slow-release formulation</li>
<li><span class="aglmd-moreinfo ui-moreinfo" data-iid="53aa2488d35d3ae92e001f48">Dual inhibition of COX-1 and COX-2 isoenzymes</span> </li>
</ol>
<p>Relative risk is greatest when first starting medication (&lt; 30 days)</p>
<h2 id="references">References</h2>
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20178131">Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6):1592-601</a></li>
</ul>
